search
Back to results

Postoperative Enteral Immunonutrition in Gastric Cancer

Primary Purpose

Gastric Cancer

Status
Completed
Phase
Phase 3
Locations
Poland
Study Type
Interventional
Intervention
Immunomodulating nutrition (Reconvan)
Standard nutrition (Peptisorb)
Sponsored by
Jagiellonian University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gastric Cancer focused on measuring immunonutrition, gastric cancer, enteral nutrition

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • gastric cancer confirmed in histopathological examination
  • elective operation due to gastric cancer
  • informed consent signed
  • age > 18 years
  • normal nutritional status or mild to moderate malnutrition

Exclusion Criteria:

  • severe malnutrition which required parenteral nutrition
  • urgent operation

Sites / Locations

  • 1st Department of General Surgery

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Study group

Control group

Arm Description

Immunomodulating nutrition (Reconvan)

Standard nutrition (Peptisorb)

Outcomes

Primary Outcome Measures

Postoperative complication rate
Complication rate during 30 days after the operation

Secondary Outcome Measures

Overall survival
5-year overall survival

Full Information

First Posted
January 1, 2016
Last Updated
February 25, 2019
Sponsor
Jagiellonian University
search

1. Study Identification

Unique Protocol Identification Number
NCT02647476
Brief Title
Postoperative Enteral Immunonutrition in Gastric Cancer
Official Title
The Impact of Postoperative Enteral Immunonutrition on Postoperative Complications and Survival in Gastric Cancer Patients
Study Type
Interventional

2. Study Status

Record Verification Date
February 2019
Overall Recruitment Status
Completed
Study Start Date
November 2004 (undefined)
Primary Completion Date
December 2010 (Actual)
Study Completion Date
October 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Jagiellonian University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Immunomodulating enteral nutrition in the perioperative period may reduce postoperative complications in cancer patients. Little is known if this effect translates to the better survival. The aim of study was to assess the impact of postoperative immunomodulating enteral nutrition on postoperative complications and survival of gastric cancer patients. The group of 98 gastric cancer patients were randomly assigned for postoperative immunomodulating enteral nutrition n=44 (Reconvan ,Fresenius Kabi), or standard enteral nutrition n=54 (Peptisorb, Nutricia). Postoperative complications, mortality, 6-month, 1-year and 5-year survival were analyzed.
Detailed Description
Treatment of gastric cancer often requires major surgery and carries the risk of postoperative complications and fatal outcomes. Mortality rates after gastrectomy due to gastric cancer have been reported as 2-5%, while the incidence of postoperative complications was 10 to over 40%. Immunomodulating enteral nutrition in the perioperative period may reduce postoperative complications in cancer patients. Little is known if this effect translates to the better survival. The aim of study was to assess the impact of postoperative immunomodulating enteral nutrition on postoperative complications and survival of gastric cancer patients. The group of 98 gastric cancer patients were randomly assigned for postoperative immunomodulating enteral nutrition n=44 or standard enteral nutrition n=54. Following the initial randomization, the patients received either standard nutrition (oligopeptide, low-fat, isocaloric, non-residue diet - Peptisorb, Nutricia) or immunomodulating nutrition (protein rich, isocaloric, no-residue diet including arginine, glutamines and omega-3 fatty acids - Reconvan, Fresenius Kabi). Postoperative complications, mortality, 6-month, 1-year and 5-year survival were analyzed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastric Cancer
Keywords
immunonutrition, gastric cancer, enteral nutrition

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
98 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Study group
Arm Type
Experimental
Arm Description
Immunomodulating nutrition (Reconvan)
Arm Title
Control group
Arm Type
Active Comparator
Arm Description
Standard nutrition (Peptisorb)
Intervention Type
Dietary Supplement
Intervention Name(s)
Immunomodulating nutrition (Reconvan)
Intervention Description
protein rich, isocaloric, no-residue diet including arginine, glutamines and omega-3 fatty acids - Reconvan, Fresenius Kabi
Intervention Type
Dietary Supplement
Intervention Name(s)
Standard nutrition (Peptisorb)
Intervention Description
oligopeptide, low-fat, isocaloric, non-residue diet
Primary Outcome Measure Information:
Title
Postoperative complication rate
Description
Complication rate during 30 days after the operation
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Overall survival
Description
5-year overall survival
Time Frame
5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: gastric cancer confirmed in histopathological examination elective operation due to gastric cancer informed consent signed age > 18 years normal nutritional status or mild to moderate malnutrition Exclusion Criteria: severe malnutrition which required parenteral nutrition urgent operation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Radosław Pach, MD PhD
Organizational Affiliation
1st Dept. of General Surgery, Jagiellonian University
Official's Role
Study Chair
Facility Information:
Facility Name
1st Department of General Surgery
City
Kraków
State/Province
Malopolska
ZIP/Postal Code
31-501
Country
Poland

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
29533110
Citation
Scislo L, Pach R, Nowak A, Walewska E, Gadek M, Brandt P, Puto G, Szczepanik AM, Kulig J. The Impact of Postoperative Enteral Immunonutrition on Postoperative Complications and Survival in Gastric Cancer Patients - Randomized Clinical Trial. Nutr Cancer. 2018 Apr;70(3):453-459. doi: 10.1080/01635581.2018.1445770. Epub 2018 Mar 13.
Results Reference
result
Links:
URL
https://doi.org/10.1016/j.pan.2018.09.008
Description
LInk to full text of the article with results summary

Learn more about this trial

Postoperative Enteral Immunonutrition in Gastric Cancer

We'll reach out to this number within 24 hrs